Breast Cancer: CALGB 49906 (Hematology Oncology Associates)

CALGB 49906: A Phase III Study of Doxorubicin/Cyclophosphamide Therapy Followed By Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks with Axillary Node-Positive or High Risk Node Negative Breast Cancer


This study involves treatment with chemotherapy to lower the risk of breast cancer returning for women that have breast cancer that has a high probability of spreading to other organs.

The purposes of this study are: 1) to compare different chemotherapy drugs in terms of side effects, survival, and disease-free survival and 2) to determine whether weekly administration of taxane chemotherapy drugs (paclitaxel and docetaxel) improves disease-free survival and overall survival when compared to the conventional (every 3 weeks) schedule.

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Cancer and Leukemia Group B
Katy D'Aprile, RN, BSN at 563-355-7733


  • University of Iowa Health Care Cancer Clinic - Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office